Τίτλος:
Novel technologies and emerging biomarkers for personalized cancer
immunotherapy
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
The culmination of over a century's work to understand the role of the
immune system in tumor control has led to the recent advances in cancer
immunotherapies that have resulted in durable clinical responses in
patients with a variety of malignancies. Cancer immunotherapies are
rapidly changing traditional treatment paradigms and expanding the
therapeutic landscape for cancer patients. However, despite the current
success of these therapies, not all patients respond to immunotherapy
and even those that do often experience toxicities. Thus, there is a
growing need to identify predictive and prognostic biomarkers that
enhance our understanding of the mechanisms underlying the complex
interactions between the immune system and cancer. Therefore, the
Society for Immunotherapy of Cancer (SITC) reconvened an Immune
Biomarkers Task Force to review state of the art technologies, identify
current hurdlers, and make recommendations for the field. As a product
of this task force, Working Group 2 (WG2), consisting of international
experts from academia and industry, assembled to identify and discuss
promising technologies for biomarker discovery and validation. Thus,
this WG2 consensus paper will focus on the current status of emerging
biomarkers for immune checkpoint blockade therapy and discuss novel
technologies as well as high dimensional data analysis platforms that
will be pivotal for future biomarker research. In addition, this paper
will include a brief overview of the current challenges with
recommendations for future biomarker discovery.
Συγγραφείς:
Yuan, Jianda
Hegde, Priti S.
Clynes, Raphael
Foukas,
Periklis G.
Harari, Alexandre
Kleen, Thomas O.
Kvistborg,
Pia
Maccalli, Cristina
Maecker, Holden T.
Page, David B. and
Robins, Harlan
Song, Wenru
Stack, Edward C.
Wang, Ena and
Whiteside, Theresa L.
Zhao, Yingdong
Zwierzina, Heinz and
Butterfield, Lisa H.
Fox, Bernard A.
Περιοδικό:
Journal for ImmunoTherapy of Cancer
Εκδότης:
BMJ Publishing Group
Λέξεις-κλειδιά:
Immune checkpoint blockade; Cancer immunotherapy; Biomarkers; Task
Force; Immune monitoring; Technology; Bioinformatics
DOI:
10.1186/s40425-016-0107-3
